Pricing

Sunesis Pharmaceuticals Inc (VIRX)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Mark A. Rothera
Employees:
20
2533 S COAST HWY 101, SUITE 210, CARDIFF, CA, 92007
858-400-8470
    Formally known as:
  • Sunesis Pharmaceuticals Inc.
  • Sunesis Pharmaceuticals, Inc.
Stock Split History
DateRatio
2011-02-15 1:6
2016-09-08 1:6
2020-09-03 1:10
Viracta Therapeutics, Inc. engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir. The company's development pipeline includesvecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available